A single-arm, open-label phase 2 trial of doxorubicin plus zalifrelimab, a CTLA-4 inhibitor, with balstilimab, a PD-1 inhibitor, in patients with advanced/metastatic soft tissue sarcomas-MedSci.cn

A single-arm, open-label phase 2 trial of doxorubicin plus zalifrelimab, a CTLA-4 inhibitor, with balstilimab, a PD-1 inhibitor, in patients with advanced/metastatic soft tissue sarcomas

Wilky, BA; Maleddu, A; Mailhot, A; Cartwright, C; Gao, D; Tellez, CM; Powers, K; Kemp, L; Therrien, N; Patel, JM; Grossman, JE; O'Day, S; Elias, AD

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16):

科室
- - 订阅+
  - 更多科室
工具
服务